Physician profile
Melissa E Caplan
NPI 1174501274
$1,229.10
in general payments reported to CMS, 2019-2025
25 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.34 · 2022: $175 · 2023: $95.35 · 2024: $281 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $190.35 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $186.04 | 2022-2025 | |
| Janssen Biotech, INC. | $129.27 | 2024-2025 | Darzalex, Rybrevant, Erleada |
| Pfizer INC. | $109.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $80.62 | 2023-2025 | Ojjaara, Blenrep, Zejula |
| Pharmacyclics LLC, An Abbvie Company | $73.42 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $72.52 | 2024-2025 | Enhertu, Tagrisso |
| Deciphera Pharmaceuticals INC. | $44.12 | 2024-2025 | Qinlock, Romvimza |
| Seagen INC. | $33.70 | 2022 | |
| Beone Medicines USA, INC. | $31.63 | 2025 | Brukinsa |
| Genzyme Corporation | $26.51 | 2023 | |
| Lilly USA, LLC | $25.19 | 2024 | Verzenio, Jaypirca |
| Celgene Corporation | $22.74 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.07 | 2024 | |
| Rigel Pharmaceuticals, INC. | $19.63 | 2023 | Rezlidhia, Tavalisse |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $19.59 | 2025 | Pyrukynd |
| Emd Serono, INC. | $17.51 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.33 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.90 | 2025 | Opdivo |
| Syndax Pharmaceuticals, INC. | $16.43 | 2025 | |
| Astellas Pharma US INC | $16.00 | 2022 | |
| Gilead Sciences, INC. | $15.98 | 2024 | |
| Eisai INC. | $15.42 | 2025 | |
| Sobi, INC | $13.73 | 2025 | |
| Exelixis INC. | $13.62 | 2025 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Caplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.